Our Activities
The CPMC hosts three dedicated working groups: one to address barriers to accessing biomarker and genetic testing for inherited mutations and inherited cancer risk, another to promote best practices in patient education about precision medicine, and a third to develop and encourage the use of standardized, patient-friendly terms for discussing testing.
-
Bianca Alvarez, ACCC
Deb Collyar, PAIR
Jessie Conta, PLUGS
David Davenport, PMC
Marcia Horn, ICAN
Christie Jett, Genetic Support Foundation
Rifeta Kajdic Hodzic, ACCC
Brandon Leonard, LUNGevity
Joan Levy, MRA
Sara Lindsey Patton, IASLC
Nikki Martin, LUNGevity
Leah McPherson, CSC
Jim Palma, Target Cancer Foundation
Chad Ramsey, OCRA
Beth Sandy, APSHO
Lisa Schlager, FORCE
Jilliane Sotelo, NSGC
Shannon Stasi, PLUGS
Pam Traxel, ACSCAN -
Tori Best, NBTS
Anne Mette Buhl, Clearity
Denisse Evans, Life Raft Group
Christie Jett, GSF
Erica Kuhn, Komen
Joan Levy, MRA
Stacie Lindsey, CCF
Nikki Martin, LUNGevity
Tracy Moore, OCRA
Martha Raymond, GICA
Rachel Saks, CSC
Jilliane Sotello, NSGC -
Christine Calafiore, CancerCare
Eric Konnick, CAP
Nikki Martin, LUNGevity
Beth Sandy, APSHO
Claire Saxton, CSC
Presentations
Understanding Barriers in Access to Biomarker Testing and Genetic Testing for Inherited Risk/Genetic Testing for Inherited Mutations (Genetic Testing)
Cancer Precision Medicine Commons work was presented at the Patient-Centered Laboratory Utilization Services (PLUGS) Annual Meeting, June 13-14, 2024. This poster summarizes surveys conducted among healthcare providers by the Commons to better define and understand access barriers for biomarker testing and genetic testing for inherited cancer risk.